Zydus Lifesciences is reportedly close to buying a US oncology drug maker in a deal valued at $100 to $150 million. The acquisition is expected to help the Indian company build its own distribution network for anti-cancer drugs in the US, while also bringing along the target’s biologic drug pipeline. A deal is expected soon.
Novo Nordisk’s partial phase out of a key insulin product in India may create a supply gap that competitors are ready to fill. Eris Pharma and its contract manufacturing partner Biocon Biologics could benefit as demand shifts and procurement patterns adjust. The move could trigger pricing and market share changes across India’s insulin landscape, with near-term opportunities for local players.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
